antimalari
chloroquin
hydroxychloroquin
use
treatment
inflammatori
diseas
year
even
today
new
indic
evolv
due
complex
mode
action
compound
due
fear
side
effect
especi
irrevers
retinopathi
use
often
limit
sideeffect
howev
consequ
excess
daili
dosag
effect
safe
therapi
need
correct
dose
e
adher
maxim
daili
dosag
mg
chloroquin
mg
hydroxychloroquin
per
kilogram
ideal
bodi
weight
actual
bodi
weight
lower
ideal
bodi
weight
actual
weight
use
calcul
dosag
observ
limit
allow
rather
safe
therapi
diseas
like
lupu
erythematosu
rem
syndrom
porphyria
cutanea
tarda
mg
chloroquineweek
cutan
sarcoidosi
dermatomyos
standard
therapi
fail
antimalari
tri
treat
syndrom
granuloma
annular
eros
lichen
planu
therapi
fail
either
combin
quinacrin
increas
effect
chloroquin
hydroxychloroquin
indispens
welltoler
essenti
drug
dermatolog
especi
suit
part
combin
scheme
exampl
corticosteroid
act
synergist
reduc
sideeffect
chloroquin
cq
hydroxychloroquin
hcq
quinacrin
antimalari
drug
may
use
treat
inflammatori
diseas
drug
approv
use
malaria
system
lupu
erythematosu
rheumatoid
arthriti
lack
interest
evid
effect
lack
financi
incent
unlik
studi
perform
time
soon
current
knowledg
thu
often
base
open
studi
patient
seri
case
report
present
review
tri
test
safe
use
correctli
drug
well
indic
present
follow
inform
appli
equal
adult
adolesc
children
chemistri
mechan
action
chloroquin
quinolin
mg
chloroquin
diphosph
mg
cq
figur
pure
white
crystallin
bittertast
powder
hydroxychloroquin
hcq
deriv
chloroquin
figur
two
substanc
differ
regard
mechan
action
pharmacokinet
toxicolog
side
effect
indic
follow
inform
appli
drug
recommend
dosag
base
clinic
relev
inform
salt
ie
chloroquin
diphosph
hydroxychloroquin
sulfat
respect
base
complex
mechan
action
chloroquinehydroxychloroquin
cqhcq
discuss
detail
elsewher
drug
effect
better
explain
variou
factor
singl
one
alon
tabl
cqhcq
immunomodulatori
antiinflammatori
antiprolif
properti
allevi
uvinduc
inflamm
inhibit
thrombocyt
aggreg
enhanc
glucos
toler
caus
increas
porphyrin
excret
effect
make
substanc
use
therapi
import
effect
result
lysosomotrop
properti
cqhcq
discuss
greater
detail
cqhcq
amphiphil
molecul
lipophil
ring
structur
hydrophil
side
chain
figur
thu
tend
deposit
interphas
instanc
phospholipid
membran
weakli
basic
molecul
academi
jddg
band
antimalari
drug
chemotherapi
agent
use
treatment
malaria
includ
drug
chloroquin
mefloquin
halofantrin
review
focus
chloroquin
hydroxychloroquin
quinacrin
also
known
mepacrin
atabrin
quinacrin
synthet
drug
develop
becam
main
antimalari
agent
use
alli
world
war
ii
chloroquin
develop
replac
quinin
hydroxychloroquin
deriv
chloroquin
beta
hydroxyl
first
synthes
despit
posit
report
success
use
older
antimalari
drug
treatment
chronic
discoid
lupu
erythematosu
dle
use
antimalari
wide
acknowledg
treatment
seri
use
quinacrin
publish
treat
dle
patient
improv
sinc
substanc
also
success
use
treat
noninfecti
inflammatori
diseas
use
restrict
howev
malaria
rheumatoid
arthriti
system
lupu
erythematosu
yet
recent
decad
dermatolog
particular
antimalari
agent
use
success
treat
number
diseas
new
use
continu
found
even
today
major
studi
drug
perform
decad
ago
thu
current
clinic
studi
use
modern
qualitybas
criteria
larg
unavail
due
agent
also
use
number
diseas
control
studi
avail
mechan
action
complex
involv
immunomodulatori
antiinflammatori
antiprolif
effect
thrombocyt
aggreg
inhibit
glucos
toler
enhanc
porphyrin
excret
increas
cq
hcq
amphiphil
molecul
primarili
accumul
lysosom
pass
membran
proton
acid
milieu
cytoplasm
posit
load
molecul
cqhcq
lose
abil
pass
membran
thu
accumul
factor
primarili
macrophag
lysosom
plasmodium
parasit
caus
malaria
intralysosom
proteas
thu
inhibit
lead
heme
accumul
toxic
parasit
human
leukocyt
lysosom
accumul
antigen
lowaffin
peptid
major
histocompat
complex
well
stimul
tolllik
receptor
inhibit
process
autoantigen
particular
diminish
thu
also
decreas
subsequ
immunolog
effect
tabl
indirect
effect
cell
enabl
agent
well
combin
immunomodulatori
drug
delay
clinic
effect
may
explain
fact
primarili
affect
antigenpres
cell
quinacrin
yellow
acridin
dye
ca
number
mepacrin
quinacrin
dihydrochlorid
longer
commerci
avail
may
order
pharmaceut
distributor
heinz
germani
http
wwwpharmavertriebheinzed
obtain
drug
england
bcm
special
http
wwwbcmspecialscouk
quinacrin
difficult
obtain
word
concentr
decreas
rapidli
first
gradual
depend
dosag
exponenti
decreas
halflif
drug
rang
hour
day
control
complianc
plasma
level
hcq
cq
concentr
hair
may
measur
quinacrin
elimin
slowli
kidney
discontinu
drug
signific
urin
level
still
detect
month
cq
elimin
unalt
urin
renal
impair
thu
significantli
prolong
halflif
drug
cq
low
level
hcq
caus
reduct
creatinin
clearanc
especi
older
patient
slow
cq
excret
given
cq
accumul
risk
side
effect
higher
patient
thu
dosag
reduc
accordingli
cq
metabol
cytochrom
liver
pharmacolog
activ
metabolit
cq
excret
stool
drug
plasma
level
depend
less
elimin
revers
diffus
agent
deep
compart
plasma
studi
report
follow
singl
dose
trace
cq
persist
plasma
erythrocyt
day
twomonth
regim
still
trace
month
skin
plasma
longterm
therapi
continu
found
plasma
erythrocyt
urin
year
last
dose
doseeffect
relationship
cq
precis
defin
hcq
low
plasma
concentr
ngml
reportedli
exacerb
system
le
higher
plasma
concentr
associ
increas
risk
advers
effect
longterm
therapi
well
acut
intox
advers
effect
avoid
observ
maximum
daili
dosag
fear
complic
antimalari
drug
irrevers
retinopathi
depend
neither
treatment
durat
cumul
overal
dose
rather
whether
maximum
daili
dosag
base
ideal
bodi
weight
exceed
maximum
daili
dosag
mgkg
ideal
bodi
weight
chloroquin
mgkg
ideal
bodi
weight
hydroxychloroquin
maximum
dosag
observ
retinopathi
concern
even
therapi
last
sever
year
studi
patient
averag
length
treatment
year
cumul
dose
g
retinopathi
occur
daili
dosag
mgkg
chloroquin
mgkg
hydroxychloroquin
nevertheless
product
inform
provid
resochin
advis
adult
cumul
dosag
exceed
g
chloroquin
per
kg
bodi
weight
g
total
dose
chloroquin
everyday
clinic
practic
given
cqhcq
store
adipos
tissu
dosag
may
adjust
accord
patient
ideal
bodi
weight
men
height
cm
women
height
cm
patient
actual
weight
ideal
dosag
adjust
accord
actual
weight
avoid
retinopathi
maximum
daili
dosag
mgkg
chloroquin
mgkg
hydroxychloroquin
exceed
longer
period
time
shortterm
administr
higher
daili
dosag
problem
may
necessari
instanc
give
initi
higher
dosag
day
rapidli
reach
therapeut
blood
level
import
note
increas
side
effect
possibl
misunderstand
prescrib
hcq
tablet
divid
tabl
patient
ideal
bodi
weight
kg
given
cq
tablet
per
day
mg
maximum
dosag
thu
mgkg
ideal
bodi
weight
patient
ideal
weight
kg
would
given
dosag
mgkg
bodi
weight
chloroquin
heavier
weight
administr
tablet
per
day
unproblemat
tabl
caution
exercis
treat
patient
actual
ideal
bodi
weight
less
kg
appli
especi
smaller
lighter
patient
particular
women
shorter
heavier
patient
patient
even
singl
tablet
halflif
cqhcq
long
day
patient
cqhcq
elimin
kidney
plasma
level
cqhcq
primarili
depend
revers
diffus
deep
compart
higher
plasma
level
shown
relat
increas
risk
side
effect
avoid
advers
effect
maximum
dosag
adjust
accord
ideal
bodi
weight
patient
chloroquin
mgkg
ideal
bodi
weight
hydroxychloroquin
mgkg
ideal
bodi
weight
care
must
taken
calcul
dosag
patient
weigh
kg
usual
women
shorter
heavier
patient
usual
dosag
mg
cq
mg
hcq
equival
dosag
given
prolong
period
time
much
kidney
liver
function
impair
dosag
must
decreas
quinacrin
administ
oral
avoid
advers
effect
dosag
exceed
mgdaili
tablet
optim
effect
achiev
month
dosag
reduc
everi
one
tablet
week
everi
month
dosag
must
decreas
patient
impair
kidney
liver
function
standard
dosag
quinacrin
mainten
dose
tabletsweek
reach
patient
experi
diarrhea
advers
effect
daili
dose
reduc
mg
low
dose
take
longer
achiev
clinic
effect
advers
effect
associ
cqhcq
discuss
greater
detail
elsewher
tabl
provid
summari
side
effect
specif
aspect
relev
daili
clinic
practic
dealt
detail
certain
symptom
rais
suspicion
drugrel
caus
test
perform
determin
whether
cqhcq
sourc
incid
specif
side
effect
base
primari
indic
malaria
much
higher
daili
dosag
typic
given
recommend
drug
interact
chloroquin
hydroxychloroquin
list
tabl
cqhcq
contraind
patient
retinopathi
therapi
may
attempt
gradual
increas
dosag
patient
hypersensit
reaction
hcq
cq
tabl
give
summari
relat
side
effect
absolut
contraind
retinopathi
rel
contraind
includ
neuromuscular
disord
myasthenia
gravi
psychos
patient
preexist
porphyria
cutanea
tarda
risk
hepat
usual
dosag
antimalari
drug
patient
dehydrogenas
defici
defici
hemolysi
rare
dosag
advis
prescrib
physician
decis
activ
assess
prior
begin
antimalari
drug
therapi
case
activ
assess
clinic
control
symptom
potenti
hemolyt
anemia
need
german
red
list
also
contain
follow
absolut
contraind
diseas
hematopoiet
system
pregnanc
nurs
combin
hepatotox
agent
combin
monoamin
oxidas
mao
inhibitor
use
also
limit
patient
sever
liver
kidney
dysfunct
psoriasi
discuss
text
acut
overdos
usual
occur
children
accident
suicid
attempt
singl
dose
mg
chloroquin
resochin
tablet
fatal
children
year
arrhythmia
cardiac
arrest
lead
death
thu
prescrib
cqhcq
tablet
must
kept
well
reach
small
children
given
cqhcq
accumul
deep
compart
drug
virtual
imposs
remov
system
complic
treatment
acut
cqhcq
intox
consider
gener
individu
daili
dose
adjust
ideal
bodi
weight
observ
tabl
cqhcq
well
toler
advers
effect
tabl
occasion
occur
especi
excess
high
daili
dosag
less
common
adequ
dose
tabl
wallac
suggest
regard
risk
side
effect
hcq
certain
advantag
although
chloroquin
effect
hcq
said
twothird
effect
cq
half
toxic
clear
howev
daili
dosag
compar
patient
experi
unspecif
symptom
tabl
treatment
may
attempt
drugfre
interv
dosag
reduct
side
effect
list
follow
mandat
stop
therapi
one
studi
one
two
patient
quinacrin
report
advers
effect
begin
therapi
daili
dose
mg
mild
revers
one
three
patient
complain
headach
dizzi
gastrointestin
symptom
diarrhea
loss
appetit
nausea
abdomin
cramp
symptom
disappear
spontan
reduc
dose
one
five
patient
discontinu
treatment
patient
report
persist
abdomin
cramp
diarrhea
symptom
effect
treat
antacid
antispasmod
challeng
retinopathi
definit
diagnosi
discuss
elsewher
still
hardandfast
criteria
diagnos
chloroquineassoci
retinopathi
diagnosi
base
subject
assess
examin
physician
although
retin
damag
highli
unlik
ideal
bodi
weight
use
determin
maximum
daili
dose
see
ophthalmolog
examin
fundoscopi
vision
field
test
color
vision
test
amsler
grid
test
advis
begin
treatment
within
first
month
therapi
annual
control
semiannu
control
patient
renal
liver
insuffici
baselin
examin
import
detect
central
red
scotoma
occur
healthi
popul
scotoma
also
occur
patient
system
lupu
result
vascul
patient
antiphospholipid
syndrom
corticosteroidinduc
diabet
care
surveil
essenti
suggest
dosag
exceed
well
older
patient
patient
longterm
continu
therapi
year
selftest
amsler
grid
test
month
figur
recommend
earli
detect
accord
british
recommend
ophthalmolog
examin
mandatori
hcq
maximum
daili
dosag
observ
clinic
control
regular
physician
appoint
ask
scintil
scotoma
poor
night
vision
difficulti
read
recogn
face
annual
vision
test
advis
consult
ophthalmologist
recommend
specif
problem
treatment
exceed
five
year
cq
deposit
cornea
anterior
stroma
visibl
use
slit
lamp
necessit
stop
treatment
less
common
hcq
vision
limit
condit
revers
discontinu
drug
small
number
patient
especi
take
higher
dosag
mgday
adolesc
accommod
disord
occur
result
direct
effect
chloroquin
smooth
muscl
ciliari
bodi
symptom
also
usual
resolv
spontan
therapi
continu
dosag
quinacrin
advers
ocular
effect
variou
skin
reaction
also
occur
hyperpigment
maculopapularlichenoid
urticari
exanthem
exfoli
reaction
dress
syndrom
hypersensit
light
hcq
reportedli
fewer
side
effect
cq
also
less
effect
patient
experi
unspecif
symptom
nausea
difficulti
concentr
cqhcq
may
continu
low
dose
interv
certain
advers
effect
warrant
stop
treatment
ophthalmolog
examin
fundoscopi
vision
field
test
color
vision
test
amsler
grid
test
recommend
start
therapi
within
first
month
treatment
annual
control
semiannu
control
patient
renal
liver
insuffici
accord
british
recommend
control
necessari
patient
take
hcq
long
dosag
limit
respect
cqhcq
deposit
cornea
critic
cqhcq
rare
caus
variou
type
rash
one
studi
report
hyperpigment
revers
yellowish
skin
discolor
onethird
patient
take
quinacrin
appear
conjunctiva
may
resembl
jaundic
normal
bilirubin
level
patient
may
blue
black
discolor
skin
nail
pigment
diminish
dose
reduc
disappear
therapi
stop
exanthem
report
patient
treat
malaria
prophylaxi
symptom
resolv
stop
therapi
treat
system
lupu
patient
mild
revers
dermat
second
world
war
lichenoid
dermat
reportedli
occur
malaria
prophylaxistherapi
daili
dose
mgdaili
mgdaili
small
number
patient
led
anhidrosi
skin
atrophi
alopecia
nail
chang
pigmentari
disord
antimalari
drug
known
occasion
exacerb
exist
psoriasi
psoriasi
contraind
cq
therapi
systemat
analysi
literatur
conclud
neither
evid
exacerb
psoriasi
patient
take
antimalari
drug
use
determin
individu
basi
normal
dosag
cqhcq
neg
effect
heart
case
report
howev
conduct
disord
cardiomyopathi
even
death
lowdos
quinacrin
psycholog
stimul
improv
drowsi
higher
dosag
howev
discontinu
drug
within
week
revers
symptom
restless
insomnia
psychos
occur
blood
count
chang
aplast
anemia
leukopenia
agranulocytosi
hemolysi
rare
almost
alway
relat
defici
author
thu
recommend
routin
measur
enzym
other
believ
unnecessari
sinc
hemolyt
effect
chloroquin
minim
quinacrin
therapi
blood
differenti
perform
everi
month
drop
hemoglobin
reticulocyt
treatment
must
stop
accord
manufactur
inform
cqhcq
taken
pregnant
women
except
treat
malaria
isol
report
sensoryneur
hear
loss
blind
birth
defect
spontan
abort
yet
harm
fetu
also
occur
lupu
flare
pregnanc
thu
decid
individu
basi
risk
associ
underli
diseas
altern
therapi
compar
potenti
side
effect
antimalari
therapi
sever
observ
studi
literatur
analys
report
hcq
may
safe
taken
pregnanc
one
prospect
random
control
studi
children
mother
lupu
treat
hcq
higher
apgar
score
anomali
addit
report
lupu
flare
compar
control
group
base
publish
report
especi
use
hcq
pregnant
women
drug
appear
safe
thu
also
recommend
use
pregnant
women
lupu
similarli
pharmacovigil
counsel
center
embryon
toxicolog
wwwembryotoxd
call
use
cqhcq
antirheumat
therapi
accept
exposur
cqhcq
thu
reason
termin
pregnanc
warrant
invas
diagnost
procedur
ultrasound
studi
may
perform
women
take
longerterm
therapi
higher
dosag
order
confirm
normal
fetal
organ
develop
cqhcq
pass
mother
fetu
birth
also
detect
urin
infant
breastf
mother
take
drug
still
report
abnorm
associ
breastfeed
therapi
quinacrin
caus
yellowish
discolor
skin
antimalari
drug
exacerb
psoriasi
conduct
disord
possibl
therapeut
dosag
rare
hemolyt
effect
associ
cqhcq
minim
benefit
risk
take
antimalari
drug
pregnanc
consid
individu
pregnant
women
treat
lupu
use
hcq
consid
safe
accord
embryotox
malaria
prophylaxi
shortterm
therapi
mother
may
continu
breastfeed
usual
longterm
highdos
therapi
decis
whether
continu
breastfeed
made
individu
basi
base
publish
report
hcq
therapi
mother
consid
accept
healthi
fullterm
infant
close
followedup
quinacrin
pass
mother
fetu
placenta
drug
administ
pregnant
nurs
women
despit
report
interfer
pregnanc
sever
studi
found
relev
hematolog
hepatotox
effect
antimalari
drug
maximum
daili
dosag
exceed
sinc
american
colleg
rheumatolog
explicitli
state
laboratori
studi
need
therapi
advis
howev
get
baselin
result
blood
differenti
liver
valu
start
antimalari
therapi
order
rule
preexist
patholog
chang
patient
take
quinacrin
blood
differenti
rare
aplast
anemia
assess
start
therapi
afterward
everi
month
later
everi
month
cutan
lupu
erythematosu
cqhcq
especi
effect
inflamm
associ
cutan
lupu
sever
report
shown
smoke
associ
develop
cutan
lupu
also
respons
rate
therapi
lower
smoker
one
patient
cutan
lupu
smoker
smoker
cutan
lupu
erythematosu
diseas
area
sever
index
clasi
score
compar
nonsmok
one
studi
found
discoid
skin
lesion
heal
spontan
patient
given
antimalari
therapi
heal
rate
doubleblind
studi
patient
dle
hcq
effect
placebo
month
year
verruc
hypertroph
plaqu
respond
well
antimalari
therapi
take
achiev
consist
plasma
concentr
recommend
therapi
administ
least
two
month
switch
smoker
shown
poorer
respons
treatment
quinacrin
mgdaili
take
effect
week
achiev
maximum
effect
week
lower
daili
dosag
take
longer
monotherapi
quinacrin
shown
lead
signific
mark
improv
treat
patient
literatur
therapi
appear
inadequ
week
treatment
discontinu
combin
anoth
medic
cq
hcq
combin
therapi
enhanc
effect
therapi
compar
monotherapi
random
doubleblind
studi
last
week
cutan
lupu
mg
hcq
equal
effect
mg
acitretin
respons
rate
associ
fewer
side
effect
literatur
case
seri
patient
lupu
pannicul
improv
take
antimalari
drug
addit
posit
result
case
report
also
individu
report
treatment
failur
improv
combin
therapi
consist
cqhcq
quinacrin
diltiazem
scle
report
respons
rate
scle
well
quinacrin
synergist
effect
studi
report
success
rate
antimalari
drug
therapi
patient
intermitt
cutan
lupu
drug
usual
take
week
begin
take
effect
patient
take
quinacrin
undergo
regular
blood
test
smoke
associ
develop
lupu
erythematosu
poorer
respons
cqhcq
patient
dle
respons
rate
inflammatori
lesion
take
week
maximum
effect
cqhcq
reach
combin
cq
hcq
quinacrin
act
synergist
cqhcq
given
monotherapi
combin
therapi
effect
lupu
pannicul
respons
rate
patient
scle
patient
intermitt
cutan
le
respond
therapi
antimalari
drug
possibl
subgroup
lymphocyt
infiltr
skin
photosensit
lupu
erythematosu
variant
well
antimalari
drug
shown
effect
compar
nonsteroid
antiinflammatori
agent
antimalari
agent
advantag
carri
lower
risk
cutan
liver
toxic
kidney
reaction
compar
immunosuppress
neither
risk
bone
marrow
suppress
opportunist
infect
base
result
systemat
review
antimalari
drug
inhibit
exacerb
longstand
sle
prolong
patient
surviv
risk
exacerb
diseas
time
higher
patient
take
placebo
given
cq
take
cq
vs
patient
take
placebo
corticosteroid
necessari
medium
level
evid
found
show
protect
effect
irrevers
organ
damag
thrombosi
loss
bone
mass
low
evid
level
report
favor
effect
blood
lipid
protect
osteonecrosi
reduct
sever
exacerb
adjuv
effect
remiss
lupusrel
nephriti
delay
develop
system
lupu
protect
effect
develop
cancer
addit
symptom
fatigu
weak
arthralgia
myalgia
seros
mucou
membran
ulcer
also
shown
improv
sle
patient
small
case
seri
also
report
synergist
effect
quinacrin
sle
thu
cqhcq
recommend
basic
treatment
major
sle
patient
never
given
alon
howev
patient
cardiac
lung
kidney
hematolog
vascularcentr
nervou
system
manifest
antimalari
drug
lead
improv
ra
half
patient
decreas
joint
swell
pain
improv
function
paramet
averag
month
treatment
patient
ra
combin
therapi
methotrex
sulfasalazin
hcq
reportedli
led
respons
rate
significantli
better
monotherapi
methotrex
respons
combin
therapi
sulfasalazinehcq
respons
rate
hcq
also
reduc
transaminas
elev
result
methotrex
acetylsalicyl
acid
base
case
report
experi
therapi
effect
rare
disord
pct
cqhcq
given
much
lower
dosag
usual
twice
weekli
mg
cq
mg
hcq
cq
may
given
monotherapi
pct
patient
normal
erythrocyt
hemoglobin
iron
level
patient
polyglobulia
elev
plasma
iron
level
combin
therapi
ie
begin
bloodlet
ml
everi
week
plu
cq
mgweekli
hcq
mgweekli
recommend
one
studi
report
averag
month
pct
resolv
treat
patient
longterm
observ
studi
pct
patient
result
biopsi
studi
show
improv
liver
morpholog
side
effect
rare
occur
proper
dosag
daili
dosag
mg
hand
trigger
potenti
fatal
porphyria
crisi
rare
diseas
occur
older
age
women
clinic
histolog
chronic
ulcer
stomat
resembl
lichen
planu
certain
immunolog
characterist
diseas
respond
topic
system
corticosteroid
respond
antimalari
agent
longerterm
therapi
lowdos
steroid
sometim
requir
cqhcq
especi
given
combin
therapi
lead
improv
symptom
associ
rheumatoid
arthriti
cqhcq
indic
rem
syndrom
patient
pct
therapi
consist
weekli
x
mg
cq
x
mg
hcq
possibl
combin
bloodlet
mg
cqdaili
trigger
porphyria
crisi
cqhcq
treatment
choic
chronic
ulcer
stomat
patient
sarcoidosi
also
skin
involv
one
random
prospect
doubleblind
studi
patient
given
therapi
month
cq
relat
signific
improv
month
month
longer
differ
group
indic
cq
similar
corticosteroid
tend
suppress
diseas
rather
cure
one
patient
seri
skin
chang
resolv
patient
allow
therapi
discontinu
patient
improv
slightli
respond
patient
lung
involv
statu
lung
improv
cq
therapi
cutan
sarcoidosi
establish
method
pulmonari
sarcoidosi
seem
respond
better
steroid
therapi
indic
administ
cq
hcq
patient
sarcoidosi
chronic
disfigur
skin
lesion
progress
extracutan
lesion
patient
steroid
therapi
contraind
adjuv
therapi
steroid
treatment
continu
neurosarcoidosi
steroid
failur
hypercalcemia
sarcoidosi
bcell
lymphoma
shown
improv
hydroxychloroquin
therapi
patient
dermatomyos
whose
skin
lesion
heal
system
steroid
therapi
variou
case
seri
shown
give
cqhcq
alon
combin
quinacrin
lead
improvementh
also
appli
dermatomyos
children
follow
indic
treatment
may
attempt
standard
therapi
fail
two
doubleblind
studi
report
laboratori
chemic
paramet
esr
signific
reduct
igg
iga
improv
clinic
paramet
one
retrospect
analysi
patient
span
year
ocular
pain
improv
dryness
eye
cornea
integr
rose
bengal
test
improv
schirmer
test
improv
minut
oral
pain
dri
mouth
well
salivari
flow
whole
treat
patient
report
improv
discrep
seen
result
may
due
start
point
therapi
therapi
perhap
effect
given
inflammatori
stage
burn
stage
diseas
patient
polymorph
light
erupt
antimalari
drug
treatment
choic
two
control
studi
cqhcq
led
improv
toler
sunlight
moder
clinic
improv
signific
reduct
exanthem
clinic
improv
impress
treatment
therefor
recommend
patient
sever
diseas
failur
topic
steroidsprotect
measur
sunlight
failur
lack
feasibl
uv
harden
number
case
report
success
use
antimalari
agent
treatment
array
skin
diseas
yet
absenc
larger
studi
imposs
compar
result
draw
solid
conclus
diseas
list
tabl
follow
discuss
thoroughli
one
open
studi
last
month
eczema
improv
significantli
patient
given
cq
allow
system
steroid
therapi
discontinu
eight
patient
moder
improv
forc
discontinu
therapi
due
advers
effect
one
case
seri
patient
hcq
reportedli
effect
corticosteroid
yet
due
unforeseen
spontan
heal
difficult
unequivoc
assess
result
case
report
seem
support
posit
effect
cqhcq
variou
inflammatori
skin
diseas
tabl
sever
case
report
one
larger
case
seri
cqhcq
use
pediatr
patient
reportedli
led
complet
resolut
gener
granuloma
anular
therapi
continu
week
clinic
resolut
patient
remain
symptomfre
year
afterward
lichen
planu
mucosa
one
patient
seri
oral
lichen
planu
improv
patient
given
hcq
pain
red
improv
month
took
month
eros
heal
heal
report
patient
cq
also
success
use
lichen
planu
lower
lip
form
lichen
planu
lightexpos
area
skin
typic
occur
middl
east
base
case
report
experi
author
appear
cqhcq
therapi
highli
effect
one
case
studi
report
lichen
planu
nail
symptom
manifest
year
earlier
regim
cq
symptom
disappear
ten
week
stop
therapi
condit
return
granuloma
anular
appear
respond
cqhcq
one
studi
eros
lichen
planu
eros
heal
respond
month
one
case
seri
patient
necrobiosi
lipoidica
improv
within
month
thrombosi
prophylaxi
antiphospholipid
syndrom
cqhcq
inhibit
thrombocyt
aggreg
one
studi
given
prevent
thrombosi
follow
hip
replac
surgeri
hydroxychloroquin
mgdaili
week
significantli
reduc
incid
pulmonari
embol
patient
anoth
studi
rate
venou
arteri
thromboembol
complic
reduc
even
subgroup
highrisk
sle
patient
phospholipid
antibodi
given
hcq
therapi
experienc
thromboembol
within
year
control
group
cqhcq
thu
given
primari
prevent
therapi
thromboembol
patient
sle
patient
exist
thromboembol
complic
anticoagul
recommend
instead
due
increas
ldl
receptor
inhibit
cholesterol
synthesi
liver
total
cholesterol
ldl
triglycerid
level
decreas
sle
patient
especi
concomit
steroid
therapi
chloroquin
reduc
blood
glucos
level
thu
act
side
effect
corticosteroid
use
chloroquinehydroxychloroquin
fallen
favor
due
sever
ocular
side
result
incorrect
dose
risk
may
minim
observ
follow
principl
incid
side
effect
depend
heavili
plasma
level
drug
turn
result
revers
diffus
cqhcq
deep
compart
antimalari
drug
store
adipos
tissu
thu
key
avoid
retinopathi
observ
maximum
recommend
daili
dosag
mgkg
chloroquin
ideal
bodi
weight
mgkg
hydroxychloroquin
especi
import
lighter
patient
especi
women
small
obes
patient
delay
elimin
due
renal
liver
dysfunct
dosag
reduc
ophthalmolog
control
first
month
therapi
advis
later
larger
interv
abovement
guidelin
follow
cqhcq
may
even
given
longer
period
time
minim
risk
none
der
einsendeschluss
die
dda
dies
ausgab
ist
der
novemb
die
richtig
zum
thema
die
photodynamisch
therapi
der
dermatologi
heft
juni
ist
bitt
verwenden
sie
ihr
einsendung
da
aktuel
formblatt
auf
der
folgenden
seit
oder
aber
geben
sie
ihr
onlin
unter
http
jddgakademieddad
ein
